Cargando…

Early recurrences predict late therapy failure after pulsed field ablation of atrial fibrillation: midterm clinical outcome from a high-volume center

FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: Pulsed field ablation (PFA) is a new myocardial-specific ablation technology for atrial fibrillation (AF). Direct current electric energy is applied to cells and disrupts cell membranes by creating pores. Data regarding midterm out...

Descripción completa

Detalles Bibliográficos
Autores principales: Plank, K, Bordignon, S, Schmidt, B, Urbanek, L, Chen, S, Schaack, D, Tohoku, S, Chun, K R J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207612/
http://dx.doi.org/10.1093/europace/euad122.700
_version_ 1785046495983042560
author Plank, K
Bordignon, S
Schmidt, B
Urbanek, L
Chen, S
Schaack, D
Tohoku, S
Chun, K R J
author_facet Plank, K
Bordignon, S
Schmidt, B
Urbanek, L
Chen, S
Schaack, D
Tohoku, S
Chun, K R J
author_sort Plank, K
collection PubMed
description FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: Pulsed field ablation (PFA) is a new myocardial-specific ablation technology for atrial fibrillation (AF). Direct current electric energy is applied to cells and disrupts cell membranes by creating pores. Data regarding midterm outcome are sparse. PURPOSE: The aim of this single-center study was to report midterm clinical outcomes following PFA-based pulmonary vein isolation (PVI). METHODS: Consecutive patients with symptomatic AF were enrolled to undergo PFA-PVI based on the "5S Study" ablation strategy. Procedures were done between March 2021 and January 2022. A dedicated catheter with five splines delivering bipolar energy with a voltage of 1.8-2.0 kV was used. Arrhythmia recurrence was defined as documented AF/atrial tachycardia (AT) lasting more than 30 seconds after a 90 days blanking period (BP). Procedural and demographic data were analysed. RESULTS: 231 patients (42% female, age 69±12, 55% paroxysmal atrial fibrillation [PAF]) were included in this preliminary analysis. 901 pulmonary veins (PV) were identified, and all PVs could be isolated using solely the PFA device. 895 (99.3 %) PVs were isolated with the first application. 32±4 applications per patient were delivered. The overall complication rate was 3.5% (vascular access complication: 2.2%, stroke: 0.9%, tamponade: 0.4%). Median follow-up time was 323 days. 22% of patients experienced a recurrence during the BP after a median of 23 days. Kaplan Meier estimated freedom of AF/AT out of the BP was 75% at one year, 83% for PAF and 64% for persistent atrial fibrillation (persAF, p< 0.0036). In a multivariate analysis blanking recurrence (p<0.001) and female sex (p=0.002) were the only independent predictors for late recurrence. CONCLUSIONS: This study indicates high acute efficacy of PFA based PVI. 75% of patients are free of AF at one year. Blanking recurrence is an independent predictor for late recurrence after PFA-PVI: further studies are required to better define the duration of the BP after PFA PVI.
format Online
Article
Text
id pubmed-10207612
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-102076122023-05-25 Early recurrences predict late therapy failure after pulsed field ablation of atrial fibrillation: midterm clinical outcome from a high-volume center Plank, K Bordignon, S Schmidt, B Urbanek, L Chen, S Schaack, D Tohoku, S Chun, K R J Europace 9.4.4 - Catheter Ablation of Arrhythmias FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: Pulsed field ablation (PFA) is a new myocardial-specific ablation technology for atrial fibrillation (AF). Direct current electric energy is applied to cells and disrupts cell membranes by creating pores. Data regarding midterm outcome are sparse. PURPOSE: The aim of this single-center study was to report midterm clinical outcomes following PFA-based pulmonary vein isolation (PVI). METHODS: Consecutive patients with symptomatic AF were enrolled to undergo PFA-PVI based on the "5S Study" ablation strategy. Procedures were done between March 2021 and January 2022. A dedicated catheter with five splines delivering bipolar energy with a voltage of 1.8-2.0 kV was used. Arrhythmia recurrence was defined as documented AF/atrial tachycardia (AT) lasting more than 30 seconds after a 90 days blanking period (BP). Procedural and demographic data were analysed. RESULTS: 231 patients (42% female, age 69±12, 55% paroxysmal atrial fibrillation [PAF]) were included in this preliminary analysis. 901 pulmonary veins (PV) were identified, and all PVs could be isolated using solely the PFA device. 895 (99.3 %) PVs were isolated with the first application. 32±4 applications per patient were delivered. The overall complication rate was 3.5% (vascular access complication: 2.2%, stroke: 0.9%, tamponade: 0.4%). Median follow-up time was 323 days. 22% of patients experienced a recurrence during the BP after a median of 23 days. Kaplan Meier estimated freedom of AF/AT out of the BP was 75% at one year, 83% for PAF and 64% for persistent atrial fibrillation (persAF, p< 0.0036). In a multivariate analysis blanking recurrence (p<0.001) and female sex (p=0.002) were the only independent predictors for late recurrence. CONCLUSIONS: This study indicates high acute efficacy of PFA based PVI. 75% of patients are free of AF at one year. Blanking recurrence is an independent predictor for late recurrence after PFA-PVI: further studies are required to better define the duration of the BP after PFA PVI. Oxford University Press 2023-05-24 /pmc/articles/PMC10207612/ http://dx.doi.org/10.1093/europace/euad122.700 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle 9.4.4 - Catheter Ablation of Arrhythmias
Plank, K
Bordignon, S
Schmidt, B
Urbanek, L
Chen, S
Schaack, D
Tohoku, S
Chun, K R J
Early recurrences predict late therapy failure after pulsed field ablation of atrial fibrillation: midterm clinical outcome from a high-volume center
title Early recurrences predict late therapy failure after pulsed field ablation of atrial fibrillation: midterm clinical outcome from a high-volume center
title_full Early recurrences predict late therapy failure after pulsed field ablation of atrial fibrillation: midterm clinical outcome from a high-volume center
title_fullStr Early recurrences predict late therapy failure after pulsed field ablation of atrial fibrillation: midterm clinical outcome from a high-volume center
title_full_unstemmed Early recurrences predict late therapy failure after pulsed field ablation of atrial fibrillation: midterm clinical outcome from a high-volume center
title_short Early recurrences predict late therapy failure after pulsed field ablation of atrial fibrillation: midterm clinical outcome from a high-volume center
title_sort early recurrences predict late therapy failure after pulsed field ablation of atrial fibrillation: midterm clinical outcome from a high-volume center
topic 9.4.4 - Catheter Ablation of Arrhythmias
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207612/
http://dx.doi.org/10.1093/europace/euad122.700
work_keys_str_mv AT plankk earlyrecurrencespredictlatetherapyfailureafterpulsedfieldablationofatrialfibrillationmidtermclinicaloutcomefromahighvolumecenter
AT bordignons earlyrecurrencespredictlatetherapyfailureafterpulsedfieldablationofatrialfibrillationmidtermclinicaloutcomefromahighvolumecenter
AT schmidtb earlyrecurrencespredictlatetherapyfailureafterpulsedfieldablationofatrialfibrillationmidtermclinicaloutcomefromahighvolumecenter
AT urbanekl earlyrecurrencespredictlatetherapyfailureafterpulsedfieldablationofatrialfibrillationmidtermclinicaloutcomefromahighvolumecenter
AT chens earlyrecurrencespredictlatetherapyfailureafterpulsedfieldablationofatrialfibrillationmidtermclinicaloutcomefromahighvolumecenter
AT schaackd earlyrecurrencespredictlatetherapyfailureafterpulsedfieldablationofatrialfibrillationmidtermclinicaloutcomefromahighvolumecenter
AT tohokus earlyrecurrencespredictlatetherapyfailureafterpulsedfieldablationofatrialfibrillationmidtermclinicaloutcomefromahighvolumecenter
AT chunkrj earlyrecurrencespredictlatetherapyfailureafterpulsedfieldablationofatrialfibrillationmidtermclinicaloutcomefromahighvolumecenter